US sales of Vasostrict totaled USD890 m for the LTM ended September 30, 2021.
On December 15, 2021, the US Food and Drug Administration approved Eagle's abbreviated new drug application for vasopressin, a product that is indicated for use to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines.
Eagle was first-to-file an ANDA referencing Par Pharmaceutical, Inc.'s Vasostrict for the 20 units per ml presentation.
On August 31, 2021, the US District Court for the District of Delaware held that Eagle's proposed vasopressin product does not infringe any of the patents Par asserted against Eagle.
Par's appeal of the District Court's ruling remains pending, and Eagle will continue to vigorously defend against such appeal.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise.
Eagle's commercialized products include Ryanodex, Bendeka, Belrapzo, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT